These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15616145)

  • 1. Topotecan in the treatment of recurrent small cell lung cancer: an update.
    Ardizzoni A
    Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life.
    Gralla RJ
    Oncologist; 2004; 9 Suppl 6():14-24. PubMed ID: 15616146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the role of topotecan in the treatment of non-small cell lung cancer.
    Stewart DJ
    Oncologist; 2004; 9 Suppl 6():43-52. PubMed ID: 15616149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of weekly topotecan in recurrent small cell lung cancer.
    Eckardt JR
    Oncologist; 2004; 9 Suppl 6():25-32. PubMed ID: 15616147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topotecan in the first-line treatment of small cell lung cancer.
    Stewart DJ
    Oncologist; 2004; 9 Suppl 6():33-42. PubMed ID: 15616148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
    Biernacka B; Krawczyk P; Buczkowski J; Siwiec A; Perzyło K; Milanowski J
    Pneumonol Alergol Pol; 2010; 78(3):192-202. PubMed ID: 20461687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topotecan in small cell lung cancer.
    Schiller JH
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-27-S20-33. PubMed ID: 9425958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
    J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
    Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan for the treatment of small-cell lung cancer.
    Nicum SJ; O'Brien ME
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):795-801. PubMed ID: 17555389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
    Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
    Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
    O'Brien ME; Ciuleanu TE; Tsekov H; Shparyk Y; Cuceviá B; Juhasz G; Thatcher N; Ross GA; Dane GC; Crofts T
    J Clin Oncol; 2006 Dec; 24(34):5441-7. PubMed ID: 17135646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient.
    Kaira K; Ishizuka T; Yanagitani N; Sunaga N; Hisada T; Mori M
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):225-7. PubMed ID: 17301532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
    von Pawel J; Schiller JH; Shepherd FA; Fields SZ; Kleisbauer JP; Chrysson NG; Stewart DJ; Clark PI; Palmer MC; Depierre A; Carmichael J; Krebs JB; Ross G; Lane SR; Gralla R
    J Clin Oncol; 1999 Feb; 17(2):658-67. PubMed ID: 10080612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances with topotecan in the treatment of lung cancer.
    O'Brien M; Eckardt J; Ramlau R
    Oncologist; 2007 Oct; 12(10):1194-204. PubMed ID: 17962613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
    Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S
    Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New advances in the second-line treatment of small cell lung cancer.
    Hurwitz JL; McCoy F; Scullin P; Fennell DA
    Oncologist; 2009 Oct; 14(10):986-94. PubMed ID: 19819917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan: a review of its efficacy in small cell lung cancer.
    Ormrod D; Spencer CM
    Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.